Expert Opinion on Biological Therapy
Overview
Expert Opinion on Biological Therapy is a peer-reviewed journal that provides authoritative insights into the latest advancements and trends in the field of biological therapy. It offers expert opinions, reviews, and original research articles on the development, efficacy, and safety of biological therapies for various diseases, including cancer, autoimmune disorders, and infectious diseases. This journal serves as a valuable resource for clinicians, researchers, and industry professionals seeking to stay updated on the rapidly evolving landscape of biological therapy.
Details
Details
Abbr.
Expert Opin Biol Ther
Start
2001
End
Continuing
Frequency
Bimonthly
p-ISSN
1471-2598
e-ISSN
1744-7682
Country
United Kingdom
Language
English
Specialties
Biology
Pharmacology
Pharmacology
Metrics
Metrics
h-index / Ranks: 3004
102
SJR / Ranks: 3202
1104
CiteScore / Ranks: 2014
8.50
JIF / Ranks: 1820
4.6
Recent Articles
1.
Ahmed N, Ma C
Expert Opin Biol Ther
. 2025 Mar;
PMID: 40082083
Introduction: Ulcerative colitis (UC) is a chronic, relapsing and remitting, inflammatory bowel disease. Monoclonal antibodies targeting interleukin (IL)-23p19 have been developed to treat chronic inflammatory diseases mediated by aberrant IL23/Th17...
2.
Salman-Monte T, Cuadrado M, Galindo M, Espinosa G, Morales E, Pego-Reigosa J, et al.
Expert Opin Biol Ther
. 2025 Mar;
PMID: 40077897
Introduction: Belimumab (BEL), an anti B-lymphocyte stimulator monoclonal antibody, is the only approved biological therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Areas Covered: This review discusses BEL's...
3.
Cohen S, Bender S, Shaberman A, Vinisko R, McCabe D
Expert Opin Biol Ther
. 2025 Mar;
:1-7.
PMID: 40070099
No abstract available.
4.
Dykes K, Ball E
Expert Opin Biol Ther
. 2025 Mar;
PMID: 40069930
Introduction: Antibody-based immunotherapies are a class of therapeutics under active investigation in clinical trials for the treatment of acute myeloid leukemia (AML). Our review provides a comprehensive examination of trials...
5.
Garcia-Alfonso P, Valladares-Ayerbes M, Munoz Martin A, Morales Herrero R, Galvez Munoz E, Prat-Llorens G
Expert Opin Biol Ther
. 2025 Mar;
:1-11.
PMID: 40066702
Introduction: Adding monoclonal antibodies to chemotherapy drastically changed the landscape of advanced colorectal cancer. The prediction of benefit from anti-EGFR therapies is mainly based on the absence of mutations in...
6.
7.
Martin C, Servais L
Expert Opin Biol Ther
. 2025 Mar;
:1-16.
PMID: 40042390
Introduction: X-linked myotubular myopathy (XLMTM) is a life-threatening congenital disorder characterized by severe respiratory and motor impairment. This disease presents significant therapeutic challenges, with various strategies being explored to address...
8.
Kiely P, Murray D
Expert Opin Biol Ther
. 2025 Mar;
:1-8.
PMID: 40035204
Objectives: Many biosimilars have been approved in both the United States of America (U.S.A.) and European Union (EU). We aim to highlight how regulatory challenges and divergent requirements between both...
9.
Bruni M, Lobefaro F, Pellegrini C, Mastrangelo M, Gualdi G, Esposito M, et al.
Expert Opin Biol Ther
. 2025 Mar;
:1-17.
PMID: 40034077
Introduction: The relationship between psoriasis, immunomodulatory therapies, and the risk of malignancies is complex and still debated. The scarcity of evidence in this field makes clinicians hesitate to prescribe biological...
10.
Bensa A, Bianco Prevot L, Moraca G, Sangiorgio A, Boffa A, Filardo G
Expert Opin Biol Ther
. 2025 Mar;
25(3):309-318.
PMID: 40028854
Introduction: The aim of this systematic review was to quantify the data available on corticosteroids (CS), hyaluronic acid, (HA), platelet-rich plasma (PRP), and cell-based therapies for knee osteoarthritis (OA) treatment....